Successful treatment of choroidal neovascularization secondary to sorsby fundus dystrophy with intravitreal bevacizumab.
The purpose of this study was to investigate the response of choroidal neovascularization (CNV) in Sorsby fundus dystrophy to intravitreal bevacizumab. Three eyes of 2 patients with CNV as a result of Sorsby fundus dystrophy were treated with intravitreal bevacizumab injections (0.05 mL, 1.25 mg bevacizumab). Best-corrected visual acuity, optical coherence tomography, and/or fluorescein angiography before and after treatment were assessed. At 33-month follow-up, after 6 intravitreal bevacizumab injections in 1 eye of the first patient, best-corrected visual acuity improved from 1.00 logarithm of the minimum angle of resolution to 0.93 logarithm of the minimum angle of resolution; there was no evidence of CNV activity on optical coherence tomography or on fluorescein angiography. At 6 weeks after 1 injection in the first patient's fellow eye, best-corrected visual acuity was stabilized at 0.00 logarithm of the minimum angle of resolution without any CNV activity on optical coherence tomography or on fluorescein angiography. At 12-week follow-up, after 1 intravitreal bevacizumab injection in 1 eye of the second patient, best-corrected visual acuity improved from 1.00 logarithm of the minimum angle of resolution to 0.00 logarithm of the minimum angle of resolution; there was no evidence of CNV activity on optical coherence tomography or on fluorescein angiography. Intravitreal bevacizumab should be considered as a safe and effective treatment for CNV secondary to Sorsby fundus dystrophy.